These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 16782417

  • 21. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers.
    Tateishi R, Shiina S, Yoshida H, Teratani T, Obi S, Yamashiki N, Yoshida H, Akamatsu M, Kawabe T, Omata M.
    Hepatology; 2006 Dec; 44(6):1518-27. PubMed ID: 17133456
    [Abstract] [Full Text] [Related]

  • 22. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
    Yamamoto K, Imamura H, Matsuyama Y, Hasegawa K, Beck Y, Sugawara Y, Makuuchi M, Kokudo N.
    Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
    [Abstract] [Full Text] [Related]

  • 23. [Clinical evaluation of PIVKA-II in patients with hepatocellular carcinoma. Detection of PIVKA-II by EIA using anti-PIVKA-II monoclonal antibody].
    Ohtani M, Ido K, Kawamoto C, Kimura K.
    Rinsho Byori; 1989 Apr; 37(4):405-9. PubMed ID: 2545953
    [No Abstract] [Full Text] [Related]

  • 24. [Follow-up studies on hepatoma developing from liver cirrhosis].
    Sakai T, Kishikawa Y.
    Nihon Naika Gakkai Zasshi; 1991 Oct 10; 80(10):1637-44. PubMed ID: 1723090
    [No Abstract] [Full Text] [Related]

  • 25. Specific molecular markers in hepatocellular carcinoma.
    Yao DF, Dong ZZ, Yao M.
    Hepatobiliary Pancreat Dis Int; 2007 Jun 10; 6(3):241-7. PubMed ID: 17548245
    [Abstract] [Full Text] [Related]

  • 26. [New clinical laboratory tests for digestive system diseases].
    Nomura F.
    Nihon Naika Gakkai Zasshi; 2001 Nov 10; 90(11):2213-8. PubMed ID: 11769518
    [No Abstract] [Full Text] [Related]

  • 27. Performance characteristics of the LiBASys des-gamma-carboxy prothrombin assay.
    Owen WE, Roberts RF, Roberts WL.
    Clin Chim Acta; 2008 Mar 10; 389(1-2):183-5. PubMed ID: 18164263
    [No Abstract] [Full Text] [Related]

  • 28. Surveillance program for early detection of hepatocellular carcinoma in Japan: results of specialized department of liver disease.
    Ando E, Kuromatsu R, Tanaka M, Takada A, Fukushima N, Sumie S, Nagaoka S, Akiyoshi J, Inoue K, Torimura T, Kumashiro R, Ueno T, Sata M.
    J Clin Gastroenterol; 2006 Mar 10; 40(10):942-8. PubMed ID: 17063116
    [Abstract] [Full Text] [Related]

  • 29. Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma.
    Van Hees S, Michielsen P, Vanwolleghem T.
    World J Gastroenterol; 2016 Oct 07; 22(37):8271-8282. PubMed ID: 27729734
    [Abstract] [Full Text] [Related]

  • 30. Gpc-3 is a notable diagnostic, prognostic and a latent targeted therapy marker in hepatocellular carcinoma.
    Zou ZQ, Ding YP, Long B, Yuh JG, Xu AL, Lang ZW, Zou SY, Liu YD, Ding K, Li YY.
    Hepatogastroenterology; 2010 Oct 07; 57(102-103):1285-90. PubMed ID: 21410073
    [Abstract] [Full Text] [Related]

  • 31. Biomarkers for the early diagnosis of hepatocellular carcinoma.
    Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T.
    World J Gastroenterol; 2015 Oct 07; 21(37):10573-83. PubMed ID: 26457017
    [Abstract] [Full Text] [Related]

  • 32. Serum markers of hepatocellular carcinoma.
    Spangenberg HC, Thimme R, Blum HE.
    Semin Liver Dis; 2006 Nov 07; 26(4):385-90. PubMed ID: 17051452
    [Abstract] [Full Text] [Related]

  • 33. [PIVKA-II as a serological marker of hepatocellular carcinoma].
    Jeong SH.
    Korean J Hepatol; 2006 Sep 07; 12(3):315-7. PubMed ID: 16998285
    [No Abstract] [Full Text] [Related]

  • 34. Surveillance and diagnosis for hepatocellular carcinoma.
    Aljabiri MR, Lodato F, Burroughs AK.
    Liver Transpl; 2007 Nov 07; 13(11 Suppl 2):S2-12. PubMed ID: 17969087
    [No Abstract] [Full Text] [Related]

  • 35. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
    Kim MJ, Bae KW, Seo PJ, Jeong IK, Kim JH, Lee BH, Bang KT, Kim DW, Song IH.
    Korean J Hepatol; 2006 Sep 07; 12(3):404-11. PubMed ID: 16998292
    [Abstract] [Full Text] [Related]

  • 36. Serum Golgi Phosphoprotein 2 level: a better marker than alpha-fetoprotein for diagnosing early hepatocellular carcinoma.
    Li X, Wu K, Fan D.
    Hepatology; 2009 Jul 07; 50(1):325. PubMed ID: 19492428
    [No Abstract] [Full Text] [Related]

  • 37. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.
    Wu C, Wang Z, Liu L, Zhao P, Wang W, Yao D, Shi B, Lu J, Liao P, Yang Y, Zhu L.
    J Gastroenterol Hepatol; 2009 Jan 07; 24(1):55-62. PubMed ID: 18823443
    [Abstract] [Full Text] [Related]

  • 38. Serum golgi phosphoprotein 2 level: a better marker than alpha-fetoprotein for diagnosing early hepatocellular carcinoma.
    Li X, Wu K, Fan D.
    Hepatology; 2009 Nov 07; 50(5):1682. PubMed ID: 19739256
    [No Abstract] [Full Text] [Related]

  • 39. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
    Gadelhak NA, Gadelhak SA, El-Morsi DA, Abdelaziz MM, Abbas AT, El-Emshaty HM.
    Hepatogastroenterology; 2009 Nov 07; 56(94-95):1417-24. PubMed ID: 19950803
    [Abstract] [Full Text] [Related]

  • 40. [Alpha-fetoprotein and its fucosylation index in the early diagnosis of hepatocellular carcinoma].
    Aoyagi Y, Mita Y, Kuroiwa T, Wakuri N, Kawai H, Kobayashi M, Igarashi M, Suda T.
    Nihon Rinsho; 2001 Oct 07; 59 Suppl 6():342-8. PubMed ID: 11761969
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.